The novel monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – shows remarkable opportunity within the treatment of acute hemolytic condition (TRALI). Developed by the company, Pritoxaximab operates by neutralizing TRALI-inducing antibodies that exist on immune cells, hence reducing the likelihood of this life-threatening event asso… Read More